Fintel reports that on May 8, 2026, TD Cowen upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Hold to Buy.
Analyst Price Forecast Suggests 21.15% Upside
As of April 28, 2026, the average one-year price target for PTC Therapeutics is $89.25/share. The forecasts range from a low of $61.61 to a high of $130.20. The average price target represents an increase of 21.15% from its latest reported closing price of $73.67 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for PTC Therapeutics is 1,143MM, an increase of 38.19%. The projected annual non-GAAP EPS is -4.99.
What is the Fund Sentiment?
There are 360 funds or institutions reporting positions in PTC Therapeutics. This is an decrease of 242 owner(s) or 40.20% in the last quarter. Average portfolio weight of all funds dedicated to PTCT is 0.11%, an increase of 40.67%. Total shares owned by institutions increased in the last three months by 6.72% to 100,738K shares. 
The put/call ratio of PTCT is 0.30, indicating a bullish outlook.
What are Other Shareholders Doing?
Rtw Investments holds 7,746K shares representing 9.34% ownership of the company. No change in the last quarter.
Janus Henderson Group holds 4,851K shares representing 5.85% ownership of the company. In its prior filing, the firm reported owning 3,774K shares , representing an increase of 22.22%. The firm increased its portfolio allocation in PTCT by 56.05% over the last quarter.
Vanguard Portfolio Management holds 4,805K shares representing 5.79% ownership of the company.
Toronto Dominion Bank holds 4,138K shares representing 4.99% ownership of the company. In its prior filing, the firm reported owning 3,247K shares , representing an increase of 21.55%. The firm increased its portfolio allocation in PTCT by 51.71% over the last quarter.
Wellington Management Group Llp holds 3,867K shares representing 4.66% ownership of the company. In its prior filing, the firm reported owning 4,919K shares , representing a decrease of 27.18%. The firm decreased its portfolio allocation in PTCT by 2.48% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
